Role of intraocular steroids for the treatment of diabetic macular edema

Bryan Propes, David Poon, Diana V. Do

Research output: Contribution to journalReview articlepeer-review


Diabetic macular edema (DME) is a common and treatable cause of moderate vision loss. Since the introduction of focal/grid photocoagulation more than two decades ago, clinicians have been searching for alternative means to prevent further vision loss or improve the vision in eyes with DME, yet laser photocoagulation remains the standard of care. The most widely employed alternative treatment for DME has been the use of intravitreal corticosteroids. Although steroids can reduce the retinal thickening associated with DME, they are associated with adverse side effects such as elevated intraocular pressure and progression of cataract. Recently, a Phase III randomized clinical trial has shown that laser photocoagulation is superior to monotherapy with a preservative-free intravitreal steroid for the treatment of DME for 24 months. Depot steroid preparations, as well as combination therapy of steroid plus laser photocoagulation, are currently being investigated for the treatment of DME.

Original languageEnglish (US)
Pages (from-to)387-393
Number of pages7
JournalExpert Review of Ophthalmology
Issue number4
StatePublished - 2009
Externally publishedYes


  • Diabetic macular edema
  • Grid photocoagulation
  • Intravitreal steroid
  • Triamcinolone

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology
  • Optometry


Dive into the research topics of 'Role of intraocular steroids for the treatment of diabetic macular edema'. Together they form a unique fingerprint.

Cite this